Konstorum Anna, Vella Anthony T, Adler Adam J, Laubenbacher Reinhard C
Center for Quantitative Medicine, UConn Health, Farmington, CT, USA.
Department of Immunology, UConn Health, Farmington, CT, USA.
J R Soc Interface. 2017 Jun;14(131). doi: 10.1098/rsif.2017.0150.
The goal of cancer immunotherapy is to boost a patient's immune response to a tumour. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumour microenvironment, immune-modulating effects of conventional treatments and therapy-related toxicities. These complexities can be incorporated into mathematical and computational models of cancer immunotherapy that can then be used to aid in rational therapy design. In this review, we survey modelling approaches under the umbrella of the major challenges facing immunotherapy development, which encompass tumour classification, optimal treatment scheduling and combination therapy design. Although overlapping, each challenge has presented unique opportunities for modellers to make contributions using analytical and numerical analysis of model outcomes, as well as optimization algorithms. We discuss several examples of models that have grown in complexity as more biological information has become available, showcasing how model development is a dynamic process interlinked with the rapid advances in tumour-immune biology. We conclude the review with recommendations for modellers both with respect to methodology and biological direction that might help keep modellers at the forefront of cancer immunotherapy development.
癌症免疫疗法的目标是增强患者对肿瘤的免疫反应。然而,有效免疫疗法的设计受到多种因素的影响,包括潜在的免疫抑制性肿瘤微环境、传统治疗的免疫调节作用以及治疗相关毒性。这些复杂性可以纳入癌症免疫疗法的数学和计算模型中,然后用于辅助合理的治疗设计。在本综述中,我们审视了免疫疗法发展面临的主要挑战范畴内的建模方法,这些挑战包括肿瘤分类、最佳治疗方案安排以及联合治疗设计。尽管存在重叠,但每个挑战都为建模者提供了独特的机会,使其能够通过对模型结果进行分析和数值分析以及优化算法来做出贡献。我们讨论了随着更多生物学信息可用而变得更加复杂的几个模型示例,展示了模型开发是一个与肿瘤免疫生物学的快速进展相互关联的动态过程。我们在综述结尾为建模者提供了关于方法学和生物学方向的建议,这可能有助于使建模者处于癌症免疫疗法发展的前沿。